Health and Healthcare
Has Alpine Immune Sciences Found the Deal of a Lifetime?
Published:
Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc. (NYSE: ABBV) for its ALPN-101 dual CD28/ICOS costimulation antagonist.
Under the terms of the agreement, Alpine will receive an upfront payment of $60 million and also will be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.
Note that prior to this move, Alpine Immune Sciences only had a market cap near $90 million.
Additionally, Alpine is eligible to receive tiered royalties on net sales of ALPN-101. In exchange, AbbVie will receive an option to an exclusive license for ALPN-101.
During this option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
Note that ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways, which play a big role in multiple autoimmune and inflammatory diseases. Lupus is an example of one of the major diseases that APLN-101 looks to treat.
So far, favorable safety and tolerability, pharmacokinetics and pharmacodynamics have been observed in a first-in-human study in adult healthy volunteers for ALPN-101.
Alpine Immune Sciences stock traded up about 100% early Thursday to $9.74, in a 52-week range of $2.05 to $15.00. The consensus price target is $11.75.
AbbVie stock was relatively flat, at $95.67 in a 52-week range of $62.55 to $99.35. The consensus price target is $100.81.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
